Precigen (PGEN)
(Delayed Data from NSDQ)
$1.55 USD
0.00 (0.00%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $1.55 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PGEN 1.55 0.00(0.00%)
Will PGEN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PGEN
Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates
Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates
PGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Buy Precigen, Inc. (PGEN) After Golden Cross?
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Tops Revenue Estimates
Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Lags Revenue Estimates
Other News for PGEN
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
6 Analysts Assess Precigen: What You Need To Know
Precigen stock rallies 17% on data for PRGN-2012 gene therapy
H.C. Wainwright Keeps Their Buy Rating on Precigen (PGEN)